Literature DB >> 2192564

Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.

M A Jenike1, L Baer, P Summergrad, W E Minichiello, A Holland, R Seymour.   

Abstract

Many agents that affect the brain's serotonergic system appear to be at least partially effective in the treatment of patients with obsessive-compulsive disorder. However, in this 10-week double-blind trial in which 10 patients received sertraline and nine received placebo, sertraline was ineffective according to four measures of obsessive-compulsive symptoms. The authors discuss the implications of these preliminary findings for the serotonergic theory of obsessive-compulsive disorder and the need to explore the role of other neurochemical systems in this disorder.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192564     DOI: 10.1176/ajp.147.7.923

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 2.  Minority participation in randomized controlled trials for obsessive-compulsive disorder.

Authors:  Monnica Williams; Mark Powers; Yeo-Gin Yun; Edna Foa
Journal:  J Anxiety Disord       Date:  2010-03

Review 3.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

4.  Obsessive compulsive neurosis : clomipramine, prolactin and therapeutic response.

Authors:  J Ananth; A Kaur; R Poland; M Wohl
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

Review 5.  Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 6.  Obsessive-compulsive disorder in elderly patients.

Authors:  C W Jackson
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 7.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.

Authors:  Darin D Dougherty; Andrew K Corse; Tina Chou; Amanda Duffy; Amanda R Arulpragasam; Thilo Deckersbach; Michael A Jenike; Nancy J Keuthen
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-30       Impact factor: 5.176

Review 9.  Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.

Authors:  Petros Skapinakis; Deborah M Caldwell; William Hollingworth; Peter Bryden; Naomi A Fineberg; Paul Salkovskis; Nicky J Welton; Helen Baxter; David Kessler; Rachel Churchill; Glyn Lewis
Journal:  Lancet Psychiatry       Date:  2016-06-16       Impact factor: 27.083

Review 10.  Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time.

Authors:  Georgios D Kotzalidis; Antonio Del Casale; Maurizio Simmaco; Lucia Pancheri; Roberto Brugnoli; Marco Paolini; Ida Gualtieri; Stefano Ferracuti; Valeria Savoja; Ilaria Cuomo; Lavinia De Chiara; Alessio Mosca; Gabriele Sani; Paolo Girardi; Maurizio Pompili; Chiara Rapinesi
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.